10x Genomics, Standard BioTools, and Illumina Q3 2024 Earnings Preview and Product Pipeline Overview

A special statement: the forecast figures in the article are all based on the summary of analysts' public information. Whether it will fail or not is not mentioned, but even if they are all correct, does performance have anything to do with stock price?

Related, but not significantly...

So, you know... Investment involves risks.

Earnings Report Date:2024Year10Month29Afternoon Session

Last quarter, the company's revenue reached6890Million USD, year-on-year growth52%, since2023Q1Marching Forward with Great Momentum.

According to analysts' forecasts collected by Futu, the forecast2024Q3Revenue6498.78"Million US dollars,"EPS -0.44。

We will focus on the following3A question:

First,WES/WGSWill the proportion continue to increase?

Second, can the growth in sample size continue?

Third, the company2025Will the forecast for annual profitability be brought forward?2024Q4？

In the past three months,GeneDxStock Price Increase80.8%。

Earnings Release Date: After Market Close on October 29, 2024

10x Genomics Falls Short of Expectations

This may be the simplest, as the relevant preliminary financial results were already disclosed on October 9, 2024.

Revenue for Q3 2024 is approximately $151.7 million.

The expected revenue from Zacks is $151.62 million, with an EPS of -$0.34.

We have three points of concern:

First, the financial guidance for 2024 Q4 and the entire year of 2024;

Second, the reasons for the significant decline in revenue in the U.S. region;

Third, the strategic positioning and arrangements for spatial biology products and single-cell series products in the future.

In the past three months, the share price of 10x Genomics has fallen by 18.34%.

Earnings Date: After Market Close on October 30, 2024

Data from Futu聚合 shows that institutions expect Standard BioTools to generate revenue of approximately $41 million in 2024Q3, with an EPS of -$0.09.

Company revenue for Q2 2024 was $37.205 million, marking a positive quarter-over-quarter growth.

If this prediction turns out wrong, the stock price probably won't look good...

We have three points of concern:

First, how did SomaLogic perform in Q3;

Second, when will SomaLogic's NGS SomaScan be launched? Should I ask Illumina?

Third, can the company reverse the downward trend in performance?

In the past three months, the share price of Standard BioTools has fallen by 25.33%.

Earnings Report Date: After Market Close on November 4, 2024

2024Q2 Illumina's own revenue forecast for Q3 is $1.075-1.085 billion.

Analysts estimate that its revenue for Q3 2024 will be $1.08 billion, basically at the upper end of Illumina's own guidance.

A recent rating from RBC Capital/Leerink Partner shows that Illumina's buy rating remains unchanged.

What we are concerned about is:

First, what is the penetration of NovaSeq X/X Plus?

Second, how are the company's new strategic initiatives progressing, including single-cell sequencing products and proteomics products?

Third, how is the performance in the China region?

In the past three months, Illumina's stock price has increased by 22.07%.

As for how these companies actually perform, we will follow up and see if the analysts will stumble...

Click to Join the Gene Club Become an Industry Elite

Currently, 600+ industry elites have joined the Gene Club.

More than 2,300 industry reports on gene technology have been published.